ClinicalTrials.gg
RecruitingNCT07350057GVHDUpdated Oct 20, 2026

A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children

A Phase 1 interventional study of 1mg /kg VIC-1911 in GVHD (Acute or Chronic), sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Shanghai Jiao Tong University School of Medicine · Phase 1, Interventional, and Prevention

How we know

Updated Oct 20, 2026Now RecruitingFirst site in China+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.

Planned enrollment
71st of 72
9 · median 53
Started
2026
with 6 others
Phase 1
10 of 81
4 open now
Primary completion
2027-01
later than 19 of 42 live
Registered
70th of 81
by date
Lead sponsor
4 of 81
Shanghai Jiao Tong University School of Medicine

Among the 81 studies in Graft vs Host Disease with a site in China, this one is the 71st largest by planned enrollment of the 72 interventional ones that give a count, is one of 7 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 19 of the 42 other live ones, and was the 70th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Graft vs Host Disease with a site in China, or all of them as a file.
02

Study summary

This study is a single arm, open label Phase Ib clinical trial, consisting of two parts: the first part is a safety introduction trial, and the second part is a dose escalation trial. In the first part, the tolerability, safety, PK characteristics, PD characteristics, and preliminary efficacy of VIC-1911 tablets in combination with PTCy and sirolimus will be explored. The first part will conduct safety introduction tests at the same dose as those already tested abroad to determine the dosage required for VIC-1911 tablets to meet safety and effective biological activity. The dose limiting toxicity (DLT) in Phase I study will be evaluated from the first administration of VIC-1911 tablets to 28 days after administration. On this basis, the second part of the experiment will be conducted to further explore the effectiveness and safety of VIC-1911 tablets combined with PTCy and sirolimus under RP2D for preventing GVHD in haplo HSCT patients after myeloablative pretreatment

03

Conditions studied

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria in order to participate in this study:

    1. Children aged 8-18, regardless of gender;
    2. Prior to the start of the study, the subjects and their legal guardians shall sign a written form;
    3. Patients diagnosed with the following blood diseases and deciding to undergo haplo :

      1. Patients diagnosed with acute myeloid leukemia or high-risk acute lymphoblastic leukemia who have achieved complete remission (CR) through induction therapy;;
      2. Patients diagnosed with myelodysplastic syndrome (MDS) and with an International Prognostic Scoring System (IPSS, please refer to Appendix 1a) score of medium risk 2 or high risk, or with severe blood cell reduction in the IPSS low-risk group, who have undergone ineffective treatment or have poor prognosis due to genetic abnormalities (such as -7,3q26 rearrangement, TP53 gene mutation, complex karyotype, monomeric karyotype);
    4. There are peripheral blood stem cell donors who are 5/10 HLA haploidentical;
    5. (KPS) score (see Appendix 2) ≥ 80 points;
    6. Possess sufficient organ functions, including:

      1. Serum creatinine ≤ 1.5 x (ULN) or calculated rate (using Cockcroft Gault formula, please refer to Appendix 3) ≥ 50ml/min;
      2. (AST) and alanine aminotransferase (ALT) are both ≤ 2 × ULN, and total is\<1.5 × ULN (for subjects with Gilbert syndrome, inclusion should be determined by researchers and medical monitors);
      3. Ferritin\<2000ng/ml;
      4. Adequate lung function, defined as , FVC, DLCO ≥ 50% of expected values; Pulmonary function test: FEV1, FVC, DLCO ≥ 50% of expected values;
      5. Adequate cardiac function, defined as a (LVEF) of ≥ 45% evaluated through echocardiography or multiple uptake gated acquisition (MUGA) scans;

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from participating in this study:

    1. Hematopoietic stem cell transplantation comorbidity index (HCT-CI)>4 (Sorror criteria, please refer to Appendix 5);
    2. Plan to start post transplant maintenance treatment within 75 days after transplantation;
    3. Those who are allergic to cyclophosphamide, VIC-1911 tablets, sirolimus, and sirolimus derivatives, or any component of the above drugs;
    4. Those who are unable or unwilling to discontinue other treatments before the start of the study;
    5. History of eye diseases, patients with central or branch retinal artery or vein occlusion, accompanied by significant visual impairment, or other retinal diseases determined by ophthalmologists leading to visual impairment;
    6. Have a serious history of cardiovascular and cerebrovascular diseases, including but not limited to:

      1. Hypertension that cannot be controlled after standard clinical treatment (systolic blood pressure>160mmHg or diastolic blood pressure>100mmHg for more than 4 weeks);
      2. Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc; According to the standards of the (NYHA) in the United States (please refer to Appendix 6), patients with III-IV grade heart failure;
      3. Within 6 months prior to the first administration, any of the following conditions have occurred: myocardial infarction, severe/unstable angina, persistent arrhythmia with v5.0 ≥ 2, atrial fibrillation of any grade, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure with CTCAE v5.0 ≥ 2, cerebrovascular accident (note: patients with lacunar cerebral infarction may be considered for inclusion);
      4. Any factors that increase the risk of prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, or the use of any known concomitant medication that may prolong the QT interval (see Appendix 7), except for antibiotics used for the prevention or treatment of infections;
    7. Those who have undergone major surgical procedures within 28 days prior to administration, or those who are expected to undergo major surgery during the trial period;
    8. During screening, there are gastrointestinal abnormalities that may affect the intake, transport, or absorption of drugs (such as swallowing difficulties, uncontrollable nausea and vomiting, active gastric ulcers, ulcerative colitis, Crohn's disease, chronic diarrhea, intestinal obstruction, etc.);
    9. Have received the drug used in clinical trials or are currently participating in clinical trials involving the drug within 28 days before administration or within 5 half lives of the drug (whichever is longer);
    10. People who have difficulty with venous blood collection;
    11. Individuals who are positive for surface antigen (HBsAg) and/or core antibodies and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA), positive for virus (HCV) antibodies and positive for hepatitis C virus ribonucleotide (HCV RNA) testing, positive for Treponema pallidum antibodies, and positive for antibodies (HIV Ab) during screening;
    12. Subjects who have used appropriate antibiotics or other treatments but still have uncontrolled systemic fungal, bacterial, viral, or other infections;
    13. Have undergone major organ surgery (excluding aspiration ) or severe trauma within 4 weeks prior to the first administration, or require elective surgery during the trial period;
    14. The researchers believe that the patient is not suitable to participate in this study (such as not meeting the most beneficial treatment for the patient, patient compliance, etc.).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Phase Ib Study of Post-Transplant Cyclophosphamide (PTCy) Combined with Sirolimus and VIC-1911 Table

    Drug: 1mg /kg VIC-1911

Interventions

  • Drug1mg /kg VIC-1911

    VIC-1911 D5-D45 1mg/kg(maximum 75mg)Oral administration on an empty stomach Bid VIC-1911 D5-D45 1.25mg/kg(maximum 75mg)Oral administration on an empty stomach Bid VIC-1911 D5-D45 0.75mg/kg(maximum 75mg)Oral administration on an empty stomach Bid

    Also known as: 1.25mg/kg VIC-1911

06

What researchers measure

Primary outcomes

  1. 1.Determine the recommended phase 2 dose (RP2D) of VIC-1911 tablets combined with post transplant cyclophosphamide (PTCy) and sirolimus for the prevention of GVHD in haplo HSCT pediatric patients (Only evaluated in Part 1)

    1. The incidence of dose limiting toxicity (DLT) during observation period; 2. When used in combination, the RP2D of VIC-1911 tablets. The dose of RP2D should achieve the minimum expected biological efficacy, and the incidence of DLT in patients at this dose should be less than 30%. The minimum expected biological efficacy is 65% of patients with CD4+pH3ser10+T cells\<54% at baseline by day 21 (-3 to+7), based on the lower confidence interval of pre transplant CD4+pH3ser10+T cell frequency (note: pH3ser10 is the phosphoprotein target of Aurora kinase A)

    Time frame: Expected 2 years

07

Study locations

1 of 1 sites recruiting
  • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • BMT Center · ContactBMT-SCMC@outlook.com · 86-021-38626161
    • Xiaodong Wang, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 39 non-industry phase 1 interventional studies under Graft vs Host Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 69. This study's planned 4 months is below that.

Counting every sponsor, half of 49 studies reached it within 47 months; a quarter within 24 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Mar 2026 → Sep 2026 and primary completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 20, 2026
StartEst.
Sep 28, 2026was Mar 2026
Primary completionEst.
Jan 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
1 site added — first site in China
Show site
  • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, China
Oct 20, 2026
Start date
Mar 25, 2026→Sep 28, 2026
Oct 20, 2026
Primary completion
Dec 1, 2026→Jan 31, 2027
Oct 20, 2026
Study completion
Dec 1, 2027→Dec 31, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine · Shanghai, China
    Start date Mar 25, 2026→Sep 28, 2026
    Primary completion Dec 1, 2026→Jan 31, 2027
    Study completion Dec 1, 2027→Dec 31, 2027
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07350057
Responsible party
wang xiaodong (Principal Investigator, Shanghai Children's Medical Center) — Principal investigator
First posted
Jan 20, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

wang xiaodong, PI
Contact
donlevin@live.cn
189 3869 1232

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion